Beyond Air (NASDAQ:XAIR) Releases Earnings Results, Misses Estimates By $0.45 EPS

Beyond Air (NASDAQ:XAIR) released its earnings results on Wednesday. The company reported ($3.76) EPS for the quarter, missing the consensus estimate of ($3.31) by ($0.45), Zacks reports. The firm had revenue of $2.32 million during the quarter, compared to the consensus estimate of $2.16 million. Beyond Air had a negative net margin of 407.31% and a negative return on equity of 577.52%.

Here are the key takeaways from Beyond Air’s conference call:

• Beyond Air reported record quarterly revenue of $2.3 million, up 28% year over year and 31% from the June quarter; gross margin improved to 8% from negative 16% a year earlier.
• The second-generation LungFit PH remains under FDA review. The company expects to complete audit readiness by mid-December, but inspection and final approval timing remain subject to the FDA.
• Management reaffirmed calendar 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million. The 2027 forecast assumes second-generation system revenue in the second through fourth quarters, pending FDA approval.
• Management said the U.S. commercial pipeline has more than doubled since it was cleaned up and is converting into new customer wins; it also cited growing renewals and strong international sales.
• The company reported a $7.8 million quarterly net loss attributable to common stockholders and $18.5 million in cash, restricted cash, and marketable securities, including funds held by subsidiaries and $4.8 million of restricted cash.

Beyond Air Price Performance

XAIR stock opened at $2.20 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.12 and a debt-to-equity ratio of 7.81. The company has a 50 day simple moving average of $2.63 and a 200 day simple moving average of $9.26. Beyond Air has a 1 year low of $1.85 and a 1 year high of $53.20.

Analysts Set New Price Targets

A number of equities analysts have recently commented on XAIR shares. Lake Street Capital assumed coverage on Beyond Air in a report on Tuesday, September 1st. They set a “buy” rating and a $10.00 price target for the company. Weiss Ratings raised Beyond Air from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.00.

About Beyond Air

Beyond Air, Inc. is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders. The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings. LungFit PH is designed to deliver inhaled nitric oxide to term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.